.sub-header{display:none;}
Lev Gerlovin, Ezra Josephson | Life Sciences
–>
Lev Gerlovin explores the future of payer response to rising drug prices and discuss strategies that manufacturers may consider to gain a competitive edge in this evolving landscape.
Potential MFN impact
Reference country selection HHS provided guidance on setting benchmark pricing by considering the lowest price among a set of reference countries, defined by...